Exclusive Summary

• - Tacrolimus XR is broadly off-patent in US/EU/JP with multiple generics, offering a clear global expansion window.
• - Lifelong use in transplant recipients with ~157k solid-organ transplants/year globally and steady growth sustains large demand.
• - As first-line CNI maintenance therapy, once-daily XR improves adherence and exposure stability versus IR.
• - XR competition is thinner than IR and supply is uneven across countries; 0.5/1 mg are high-rotation titration strengths suited for tenders.
• - API complies with JP/BP/USP/EP, enabling multi-region filings and compelling price advantages versus originators.